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Medication rashes are among the
most common adverse effects
caused by medications, affecting
2 to 3% of hospitalized patients.1
Outside of the hospital, approximately 1% of outpatients are affected by adverse cutaneous reactions. These reactions can
range from mild to severe and
may or may not be mediated by
the immune system. Rashes can
generally be categorized into 3
groups: 1) rashes that are caused
by an allergic reaction to a medication; 2) rashes that are due to a
side effect of a medication; or
3) rashes due to hypersensitivity
to sunlight that is caused by a
medication.2
The rashes are usually mild and
self-limiting. However, some
rashes, such as toxic epidermal
necrosis (TEN), which has a
mortality rate of up to 30% can

be severe and life-threatening.3
Certain patient populations are
more likely to develop adverse
cutaneous rashes and skin eruption, including women, elderly
patients, HIV or AIDS patients
and pediatric patients (boys >9
years old, girls >3 years old).4
Several medications are likely to
cause cutaneous reactions and are
listed in Table 1.5
Most drug eruptions are due to
immunologically mediated reactions that can be divided into 4
classes.
▪ Type I reactions are IgEdependent reactions and can result in urticaria, angioedema, and
anaphylaxis.
▪ Type II reactions are cytotoxic
and result in hemolysis and purpura.

Table 1: Products Known To Cause Drug Rashes
Drug
Rate (%)
Amoxicillin
5.1
Ampicillin
4.5
Co-trimoxazole
3.7
Semi-synthetic penicillins
2.9
Red blood cells
2.0
Penicillin G
1.6
Cephalosporins
1.5
Gentamicin
1.0
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▪ Type III reactions are related to
immune complexes, which can
cause serum sickness and urticaria.
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Non-immunologically mediated
reactions occur due to the direct
release of mast cell mediators
and do not involve the production of antibodies. An example
includes red man syndrome,
which occurs when the administration of vancomycin is too
rapid.

Although
most
medicationinduced reactions occur within the
first week after initiation, some
medications are more likely to
cause delayed reactions.6 It can
▪ Type IV reactions are delayedalso be difficult to determine the
type reactions that can result in
causative agent when the patient is
contact dermatitis and exantheon several medications and a dematous reactions.9 The majority
layed reaction occurs. Table 2
of drug eruptions are due to type
lists the different type of cutanethis type of reaction.
ous reactions that can occur and
There are several types of rashes
the medications associated with
and each type can be caused by
these syndromes.6
different classes of medications.
Table 2: Different rash classifications and the medications most likely to cause them
Type of Rash
Medications
Exanthematous drug eruptions
(ie, morbiliform/maculopapular rash)
Acne
Drug hypersensitivity syndrome
Urticaria (hives)
Angioedema
Fixed drug eruptions
Stevens-Johnson syndrome and TEN
Photosensitivity reactions
Exanthematous Drug Eruptions
Exanthematous drug eruptions, or
morbiliform rashes, are the most
common cutaneous skin reaction
and represent approximately 95%
of all drug eruptions. They are
often indistinguishable from viral
exanthems.10 Eruptions are generally widespread with fine pink to
red lesions that start on the head
and neck and can spread quickly.7
Distribution is typically symmetrical and itching is the most common symptom. The onset is usually within 1 to 2 weeks of initia-

Allopurinol, amoxicillin, captopril, carbamazepine, enalapril,
lithium, phenytoin, sulfonamides, and thiazides
Corticosteroids, iodides, lithium and phenytoin
Carbamazepine, phenytoin, lamotrigine, sulfonamides,
allopurinol, dapsone, and nitrofurantoin
Angiotensin converting enzyme (ACE) inhibitors, anticonvulsants,
cephalosporins, opiates, nonsteroidal anti-inflammatory drugs
(NSAIDs), proton pump inhibitors, penicillin, and sulfonamide
ACE inhibitors, acetaminophen, amoxicillin, ampicillin,
hydrochlorothiazide, naproxen, penicillin, and
sulfamethoxazole-trimethoprim
Acetaminophen, allopurinol, chloral hydrate, metronidazole,
penicillin, sulfamethoxazole-trimethoprim, and tetracyclines
Allopurinol, amoxicillin, ampicillin, carbamazepine,
corticosteroids, phenytoin, sulfa drugs, and valproic acid
NSAIDs, quinolones, tetracyclines, and amiodarone
tion and resolves within a week
after discontinuation. Medications may be continued with this
type of rash when no alternative
therapies are available.4
Acne
Drug-induced acne eruptions
typically mimic acne vulgaris. It
usually begins with an inflammatory pustule, and comedones
are rare.4 This rash typically has
a follicular pattern located primarily on the upper body. The
eruptions heal without scarring

and can appear in atypical areas
like the legs and arms. Treatment
generally includes discontinuation
of the drug, if possible.
Drug Hypersensitivity Syndrome
Drug hypersensitivity syndrome is
potentially life-threatening. It is
often is associated with rash, fever, and internal organ involvement. A reaction typically occurs
2 to 6 weeks after the drug is initiated and is not related to dose. It
occurs most frequently with the
first exposure to the drug. Rash
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occurs in approximately 87% of
patients and can result in StevenJohnsons syndrome.7 Treatment
involves rapid withdrawal of the
causative agent and systemic steroids are often needed.
Urticaria
Urticaria, also known as hives, is
a common transient skin eruption.
It is characterized by raised, red
eruptions that are pruritic. Hives
may occur at any age, with up to
20% of the population having at
least 1 episode during their lifetime.10 Chronic urticaria is a condition in which hives last more
than 6 weeks and is more common
in middle-aged women. Druginduced urticaria is responsible for
almost 5% of cutaneous reactions.4 Reactions can be immediate or delayed and commonly occur during the first week of treatment. The primary treatment for
urticaria is an antihistamine and
discontinuation of the offending
agent.
Angioedema
Angioedema involves subcutaneous and dermal tissues and is
characterized by a hive-like swelling caused by increased vascular
permeability. It may occur with
or without urticaria and itching is
usually absent. Angioedema commonly occurs on the lips, face,
and eyes. It may be disfiguring or
potentially life threatening if airway obstruction occurs.6 Gastrointestinal symptoms may occur as
well. Antihistamines (H1) are the
gold-standard treatment for angioedema.4 In severe cases, systemic corticosteroids may be
needed for therapy but immediate
effects should not be expected.
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Fixed Drug Eruptions
Fixed drug eruptions are relatively common and represent a
distinctive dermatologic reaction. Eruptions typically occur
on the mouth, face and genitals.
They are demarcated, round, hyperpigmented plaques that reoccur in the same place if reexposed to the medication. For
unknown reasons, women are
more affected by fixed drug
eruptions than men.7 Treatment
involves discontinuing the medication; topical steroids may be
needed.
Stevens-Johnson Syndrome
and TEN
Stevens-Johnson syndrome and
TEN are severe cutaneous reactions that can result in significant
morbidity and mortality. It consists of purpuric lesions with
mucosal involvement. Constitutional symptoms such as high
fever, nausea, and vomiting are
generally present.
Epidermal
skin detachment is less than 10%
of the body surface. TEN is a
continuation of Stevens-Johnson
syndrome and is characterized
by more than 30% of epidermal
detachment. Mortality rates are
5% for Stevens-Johnson syndrome and up to 30% for TEN.
Penicillins and sulfonamiderelated medications are most
commonly involved in these disorders.8 Stevens-Johnson syndrome and TEN can result in
severe fluid loss, infections, and
increased energy requirements.
Rapid discontinuation of the offending drug is required and supportive therapy is recommended.
The use of corticosteroids has
been controversial and is no
longer recommended.7

Photosensitivity Reactions
Photosensitivity eruptions are due
to the combined effects of sunlight
and a chemical such as a medication. Phototoxic eruptions are the
most common cause of druginduced photoeruptions.
The
eruption is usually manifested by
an exaggerated sunburn with blisters. Reactions can be immediate
or delayed. Treatment involves
avoidance of the medication or
avoiding sunlight exposure. It is
also recommended to limit skin
exposure to the sun by wearing
long-sleeved clothing and hats.
Sunscreen should also be used to
help protect against photosensitivity reactions. Broad-spectrum sunscreens that have a sun protection
factor (SPF) of at least 30 are recommended. Sunscreens should
also be para-aminobenzoic acid
(PABA) free, as this can exacerbate photosensitivity reactions.11
Cutaneous drug reactions are a
major cause of adverse drug reactions. Patients that are on multiple
medications are at a higher risk
for developing a medication rash.
If an adverse event occurs, the
agent should be identified and discontinued if possible. Treatment
of medication eruptions depends
on the specific reaction that occurs. Patients that have experienced a hypersensitivity or severe
reaction in the past need to have
their therapy closely monitored to
help ensure these reactions do not
reoccur. The aim is to prevent the
recurrence and not to compromise
future treatments by contraindicating otherwise useful medications.
The situation should be thoroughly assessed to determine the
actual causality.
References available upon request
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Did You Know...
FDA Statement on Antiepileptic Drugs and Suicidality
Food and Drug Administration (FDA) issued a statement on December 16, 2008, as a follow-up to their January 2008 warning, on the increased risk of suicide associated with 11 antiepileptic medications. A warning
will be added to the labeling of the following medications:
▪ Carbamazepine (Tergretol®,Carbatrol®, Tegretol-XR®)
▪ Felbamate (Felbatol®)
▪ Gabapentin (Neurontin®)
▪ Lamotrigine (Lamictal®, Lamictal CD®)
▪ Levetiracetam (Keppra®, Keppra XR®)
▪ Oxcarbazepine (Trileptal®)
▪ Pregabalin (Lyrica®)
▪ Tiagabine (Gabitril®)
▪ Topiramate (Topamax®)
▪ Valproate (Depacon®)
▪ Zonisamide (Zonegran®)
Manufacturers must also develop a medication guide that can be provided to patients prescribed these medications. Healthcare professionals should be aware of the potential for this risk and monitor patients for changes
in behavior that might indicate depression or suicidal thoughts. More information is available at:
http://www.fda.gov/medwatch/safety/2008/safety08.htm#Antiepileptic.
Update of Safety Review on Ezetimibe/Simvastatin (Vytorin®)
FDA released an update on its analysis of data from the ENHANCE trial1 (Effect of Combination Ezetimibe
and High-Dose Simvastatin vs. Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia) on January 9, 2009. Preliminary results from this investigation found
that the combination of ezetimibe and simvastatin did not significantly reduce carotid (neck) artery thickness
more than simvastatin alone, even though the ezetimibe/simvastatin reduced low-density lipoprotein (LDL) to
a significantly greater degree. FDA communication indicates that this information does not change the
agency’s stance that lowering LDL cholesterol reduces the risk of cardiovascular disease. Patients should remain on their prescribed medications and speak with their physicians if they have questions about ezetimibe,
simvastatin, or the ENHANCE trial. An ongoing clinical trial, expected to be completed in 2012, will help
better determine whether the combination of ezetimibe and simvastatin reduces the risk of cardiovascular
events compared with simvastatin alone. More information is available at:
http://www.fda.gov/cder/drug/early_comm/ezetimibe_simvastatin200901.htm.
1

Kastelein JJP, Akdim F, Stroes ESG, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without ezetimibe in
familial hypercholesterolemia. N Engl J Med. 2008;358(14):1431-43.

FDA Statement on Topical Anesthetics
On January 16, 2009, FDA issued a public health advisory stating that skin numbing products, or topical anesthetics (such as lidocaine), often used to relieve pain caused by mammography or other medical tests and conditions, can cause serious life-threatening complications. These risks include irregular heartbeat, seizures,
breathing difficulties, coma, and even death and are seen when the preparation is applied to a large area of skin
or a covering is placed over the application area of the product. More information is available at:
http://www.fda.gov/medwatch/safety/2009/safety09.htm#Anesthetics.

